首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious beta-secretase inhibitors for the potential treatment of Alzheimer's disease
【24h】

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious beta-secretase inhibitors for the potential treatment of Alzheimer's disease

机译:开发2-氨基恶唑啉3-氮杂蒽酮作为口服有效的β-分泌酶抑制剂,可潜在治疗阿尔茨海默氏病

获取原文
获取原文并翻译 | 示例
           

摘要

The beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) is one of the most hotly pursued targets for the treatment of Alzheimer's disease. We used a structure-and property-based drug design approach to identify 2-aminooxazoline 3-azaxanthenes as potent BACE1 inhibitors which significantly reduced CSF and brain Ab levels in a rat pharmacodynamic model. Compared to the initial lead 2, compound 28 exhibited reduced potential for QTc prolongation in a non-human primate cardiovascular safety model. (C) 2015 Elsevier Ltd. All rights reserved.
机译:β位淀粉样蛋白前体蛋白(APP)裂解酶1(BACE1)是治疗阿尔茨海默氏病最热门的靶标之一。我们使用基于结构和特性的药物设计方法来确定2-氨基恶唑啉3-氮杂蒽酮为有效的BACE1抑制剂,可在大鼠药效学模型中显着降低CSF和脑Ab水平。与初始铅2相比,化合物28在非人类灵长类心血管安全性模型中表现出降低的QTc延长潜力。 (C)2015 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号